Novartis-Aktie fester: Novartis peilt bis 2022 mehr als 80 Zulassungsanträge an – Medicines-Offerte läuft bis 3.1.

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny